2023 World Conference on Lung Cancer (Posters)-P2.06. First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN

P2.06. First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN - PDF(Abstract)

Back to course

Pdf Summary

The CAP-BRAIN trial evaluated the efficacy and safety of first-line camrelizumab plus pemetrexed and carboplatin in patients with advanced non-squamous non-small-cell lung cancer (NSCLC) and brain metastases. The trial, conducted in China, included patients with no known EGFR or ALK alterations and no previous systemic therapy. The primary endpoint was the confirmed intracranial objective response rate (iORR). <br /><br />Out of the 45 patients enrolled and treated in the study, 40 had at least one post-baseline tumor assessment. The updated iORR was 57.5% in the efficacy analysis set and 51.1% in the full analysis set. The updated median intracranial progression-free survival was 8.4 months, with 6-month and 12-month progression-free survival rates of 66.8% and 47.1%, respectively. The median overall progression-free survival was 7.2 months, with 6-month and 12-month rates of 55.9% and 35.5%, respectively. The median overall survival was 19.7 months, and the estimated 12-month survival rate was 65.9%.<br /><br />Grade 3 or above treatment-related adverse events occurred in 35.6% of patients, but no new safety signals were observed during extended follow-up. Patients' cognitive ability and quality of life showed positive trends. Among patients with progressive disease, antiangiogenic agents plus chemotherapy, chemotherapy alone, and immunotherapy plus chemotherapy were the most common second-line treatment strategies.<br /><br />In conclusion, the extended follow-up from the CAP-BRAIN trial confirms the promising clinical outcomes of camrelizumab plus pemetrexed and carboplatin as first-line treatment for advanced non-squamous NSCLC with brain metastases.

Asset Subtitle

xue hou

Meta Tag

Speaker xue hou

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

CAP-BRAIN trial

camrelizumab

pemetrexed

carboplatin

NSCLC

brain metastases

intracranial objective response rate

tumor assessment

progression-free survival

treatment-related adverse events